CD5+ B lymphocytes in high-risk islet cell antibody-positive and newly diagnosed IDDM subjects
- PMID: 1718800
- DOI: 10.2337/diab.40.10.1314
CD5+ B lymphocytes in high-risk islet cell antibody-positive and newly diagnosed IDDM subjects
Abstract
Human CD5+ B lymphocytes produce autoantibodies that bind to self- and exogenous antigens. Extremely high percentages of CD5+ B lymphocytes are present in the fetal and newborn periods, whereas they constitute only a minority of B lymphocytes in healthy adults. Increased percentages of circulating CD5+ lymphocytes have previously been demonstrated in several autoimmune diseases, including rheumatoid arthritis, progressive systemic sclerosis, Graves' disease, and Sjögren's syndrome. We measured the percentages of B lymphocytes that expressed the CD5 determinant in 93 control subjects (age range 1 day to 59 yr, mean +/- 22.6 +/- 17.7 yr), 17 subjects with newly diagnosed insulin-dependent diabetes mellitus (IDDM; range 5-29 yr, mean +/- SD 13 +/- 5.9 yr), 31 high-risk islet cell antibody (ICA)-positive nondiabetic subjects (range 4-45 yr, mean +/- SD 19.8 +/- 14.1 yr), and 13 subjects with IDDM of greater than 5 yr duration (range 10-43 yr, mean +/- SD 24.2 +/- 9.9 yr). We report that CD5+ B-lymphocyte percentages are strikingly age dependent in healthy control subjects, declining progressively from the newborn period to the middle-age years (r = -0.75, P = 0.0001). In ICA+ nondiabetic and recent-onset IDDM subjects less than 29 yr of age, the percentage of circulating CD5+ B lymphocytes fell within the 95% confidence intervals established for control subjects. However, the age-dependent rate of decline in the percentage of CD5+ B lymphocytes within the control range was slower in ICA+ and newly diagnosed IDDM subjects than in control subjects.
Similar articles
-
Anti-islet cell and anti-insulin antibody production by CD5+ and CD5- B lymphocytes in IDDM.Diabetologia. 1995 Jan;38(1):62-72. doi: 10.1007/BF02369354. Diabetologia. 1995. PMID: 7538087
-
Enhanced percentage of CD5+ B lymphocytes in newly diagnosed IDDM patients.Immunol Lett. 1990 Jan;23(3):211-5. doi: 10.1016/0165-2478(90)90194-u. Immunol Lett. 1990. PMID: 1689697
-
Fetal type lymphocytes in insulin dependent diabetes mellitus.Autoimmunity. 1999;30(2):63-9. doi: 10.3109/08916939908994762. Autoimmunity. 1999. PMID: 10435718
-
The importance of CD5-positive B cells in nonorgan-specific autoimmune diseases.Scand J Rheumatol Suppl. 1988;76:243-9. doi: 10.3109/03009748809102975. Scand J Rheumatol Suppl. 1988. PMID: 2471999 Review.
-
The role of CD5-expressing B cells in health and disease (review).Int J Mol Med. 1999 Mar;3(3):239-45. doi: 10.3892/ijmm.3.3.239. Int J Mol Med. 1999. PMID: 10028047 Review.
Cited by
-
Expansion of FasL-Expressing CD5+ B Cells in Type 1 Diabetes Patients.Front Immunol. 2017 Apr 7;8:402. doi: 10.3389/fimmu.2017.00402. eCollection 2017. Front Immunol. 2017. PMID: 28439273 Free PMC article.
-
Hiding in plain sight: time to unlock autoimmune clues in human CD5+ B cells by using nextgen technology.Discov Med. 2018 Sep;26(142):79-83. Discov Med. 2018. PMID: 30399325 Free PMC article.
-
NOD mice are defective in proteasome production and activation of NF-kappaB.Mol Cell Biol. 1999 Dec;19(12):8646-59. doi: 10.1128/MCB.19.12.8646. Mol Cell Biol. 1999. PMID: 10567588 Free PMC article.
-
Anti-islet cell and anti-insulin antibody production by CD5+ and CD5- B lymphocytes in IDDM.Diabetologia. 1995 Jan;38(1):62-72. doi: 10.1007/BF02369354. Diabetologia. 1995. PMID: 7538087
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous